

GLAXOSMITHKLINE PLC

Form 6-K

July 16, 2013

FORM 6-K

SECURITIES AND EXCHANGE COMMISSION  
Washington D.C. 20549

Report of Foreign Issuer

Pursuant to Rule 13a-16 or 15d-16 of  
the Securities Exchange Act of 1934

For period ending July 2013

GlaxoSmithKline plc  
(Name of registrant)

980 Great West Road, Brentford, Middlesex, TW8 9GS  
(Address of principal executive offices)

Indicate by check mark whether the registrant files or  
will file annual reports under cover Form 20-F or Form 40-F

Form 20-F  Form 40-F

--

Indicate by check mark whether the registrant by furnishing the  
information contained in this Form is also thereby furnishing the  
information to the Commission pursuant to Rule 12g3-2(b) under the  
Securities Exchange Act of 1934.

Yes No

--

Notification of Transactions of Directors, Persons Discharging  
Managerial Responsibility or Connected Persons

The Administrators of the GlaxoSmithKline 2009 Deferred Annual Bonus Plan (the Plan) notified the Company and the under-mentioned persons on 16 July 2013 of the following increases in their notional interests in Ordinary Shares and American Depositary Shares (ADSs) at a price of 1753 pence per Ordinary Share and \$52.29 per ADS following the re-investment of dividends paid to shareholders on 11 July 2013.

Sir Andrew Witty Acquisition of 1,238 Ordinary Shares under the personal contribution element of the Plan.

Acquisition of 1,238 Ordinary Shares under the matching element of the Plan (Company contribution).

Mr S Dingemans Acquisition of 444 Ordinary Shares under the personal contribution element of the Plan.

Acquisition of 444 Ordinary Shares under the matching element of the Plan (Company contribution).

Dr M M Slaoui Acquisition of 611 ADSs under the personal contribution element of the Plan.

Acquisition of 611 ADSs under the matching element of the Plan (Company contribution).

Mr S M Bicknell Acquisition of 186 Ordinary Shares under the personal contribution element of the Plan.

Acquisition of 186 Ordinary Shares under the matching element of the Plan (Company contribution).

Mrs D P Connelly Acquisition of 108 ADSs under the personal contribution element of the Plan.

Acquisition of 108 ADSs under the matching element of the Plan (Company contribution).

Mr R G Connor Acquisition of 50 Ordinary Shares under the personal contribution element of the Plan.

Acquisition of 50 Ordinary Shares under the matching element of the Plan (Company contribution).

Mr W C Louv Acquisition of 90 ADSs under the personal contribution element of the Plan.

Acquisition of 90 ADSs under the matching element of the Plan (Company contribution).

Acquisition of 292 Ordinary Shares under the personal contribution element of the Plan.

Mr D S  
Redfern

Acquisition of 292 Ordinary Shares under the matching element of the Plan (Company contribution).

Ms C  
Thomas

Acquisition of 188 Ordinary Shares under the personal contribution element of the Plan.

Acquisition of 188 Ordinary Shares under the matching element of the Plan (Company contribution).

Mr P C  
Thomson

Acquisition of 9 Ordinary Shares under the personal contribution element of the Plan.

Acquisition of 9 Ordinary Shares under the matching element of the Plan (Company contribution).

Mr D E  
Troy

Acquisition of 290 ADSs under the personal contribution element of the Plan.

Acquisition of 290 ADSs under the matching element of the Plan (Company contribution).

Dr P J T  
Vallance

Acquisition of 623 Ordinary Shares under the personal contribution element of the Plan.

Acquisition of 623 Ordinary Shares under the matching element of the Plan (Company contribution).

Ms E  
Walmsley

Acquisition of 248 Ordinary Shares under the personal contribution element of the Plan.

Acquisition of 248 Ordinary Shares under the matching element of the Plan (Company contribution).

The notional dividends accrued will be paid out in proportion to the percentage of the participant's deferred annual bonus holdings that will vest following the end of the relevant measurement period.

This notification relates to a transaction notified in accordance with Disclosure and Transparency Rule 3.1.4R(1)(a).

V A Whyte  
Company Secretary

16 July 2013

SIGNATURES

Edgar Filing: GLAXOSMITHKLINE PLC - Form 6-K

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorised.

GlaxoSmithKline plc  
(Registrant)

Date: July 16, 2013

By: VICTORIA WHYTE

-----

Victoria Whyte  
Authorised Signatory for and on  
behalf of GlaxoSmithKline plc